OR WAIT null SECS
CDC tuberculosis lead Dr. Phillip LoBue joins to discuss the past and present issues of the disease, in time for TB Awareness Day on March 24.
0:17 The history of tuberculosis
5:30 Important dates in tuberculosis history
6:05 Introducing Philip LoBue, MD
7:54 Getting into tuberculosis research
9:44 Where TB still persists in the US
12:55 Latent TB infection care
19:51 The booster phenomenon
23:04 Currently available TB drugs
25:50 Managing and prescribing in the US
27:02 Key TB treatment recommendations
28:04 Drug-resistant TB care
31:39 CDC TB elimination strategies
35:34 Takehome messages
38:35 Outro
Greatly burdened with rampant cases and no certain treatment just a century ago, the US has become a model for reduced prevalence and severity of the respiratory infection in modern day.
Still, nearly 9000 new TB cases were reported in 2019, and the rate of latent TB infections is estimated up to 13 million. The goal of tuberculosis elimination is far from reached in even the US, but progress has been substantial.
In commemoration of World TB Day on March 24—the date reflecting Dr. Robert Koch’s discovery of Mycobacterium tuberculosis in 1882—this month’s episode of Lungcast features a discussion on TB history and possible elimination with a national thought leader.
Philip LoBue, MD, Director of Tuberculosis Elimination at the US Centers for Disease Control and Prevention (CDC) National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, joins the March episode to provide expert perspective on everything occurring in the respiratory infection.
Lungcast is a monthly podcast series from HCPLive and the American Lung Association (ALA), hosted by ALA chief medical officer Al Rizzo, MD.
Rizzo and LoBue reflect on the storied history of tuberculosis in the US—and their respective institutions’ work in helping mitigating it—as well as the current regimen of care available for affected patients.
Subscribe or listen to Lungcast on your favorite platforms:
Related Content:
